Date published: 2025-12-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

H2-22 Inhibitors

The H2-22 Inhibitors chemical class is a collection of compounds with diverse biochemical mechanisms aimed at modulating cellular signaling pathways and processes that can potentially influence the activity of proteins encoded by the H2-22 gene. This class includes inhibitors primarily targeting key signaling molecules involved in cell growth, survival, and proliferation, reflecting the complex interplay of pathways that regulate protein functions.

The class starts with Trastuzumab and Pertuzumab, both targeting the HER2/neu receptor. These compounds exemplify the class's ability to influence cell signaling pathways related to growth and proliferation, crucial for the modulation of protein functions, including those potentially similar to H2-22. Lapatinib and Afatinib, targeting both EGFR and HER2, further emphasize the class's role in disrupting key cell signaling pathways, impacting protein activities related to cell proliferation and survival.

Erlotinib and Gefitinib, both EGFR inhibitors, demonstrate the class's focus on modulating cell signaling pathways crucial for cell growth and differentiation. Their mechanisms of action are pivotal in understanding how these compounds can influence protein functions, particularly those related to signal transduction and cellular communication.

Cetuximab and Panitumumab, also targeting EGFR, reinforce the class's emphasis on modulating cell signaling pathways. These inhibitors have the potential to alter the activity of proteins involved in cell growth and signaling, providing insights into the modulation of proteins similar to those encoded by H2-22.

Neratinib, targeting HER2 and EGFR, along with Osimertinib, a third-generation EGFR inhibitor, demonstrate the class's broad spectrum of activity in affecting critical cell signaling pathways. Dacomitinib, another EGFR inhibitor, and Vandetanib, targeting RET, VEGFR, and EGFR, further exemplify the class's ability to modulate several critical signaling pathways.

In summary, the H2-22 Inhibitors represent a diverse array of compounds capable of interacting with various cellular mechanisms and pathways. Their interactions, achieved through targeting critical signaling molecules, offer valuable insights into how such compounds could influence the function of proteins akin to those encoded by H2-22. This class demonstrates the intricate nature of cellular signaling and its profound impact on protein activity and function, underscoring the potential of these inhibitors in modulating key cellular processes.

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Lapatinib

231277-92-2sc-353658
100 mg
$412.00
32
(1)

Targets EGFR and HER2, Lapatinib can disrupt key cell signaling pathways, influencing protein activity.

Afatinib-d4

850140-72-6 (unlabeled)sc-481821
10 mg
$4665.00
(0)

An EGFR inhibitor, Afatinib can affect cell proliferation and survival, impacting protein functions.

Erlotinib Hydrochloride

183319-69-9sc-202154
sc-202154A
10 mg
25 mg
$74.00
$119.00
33
(1)

Targets EGFR, Erlotinib can modulate cell signaling pathways, potentially affecting H2-22 protein functions.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$62.00
$112.00
$214.00
$342.00
74
(2)

Inhibits EGFR, Gefitinib can affect cell growth and survival pathways, influencing protein activity.

Neratinib

698387-09-6sc-364549
sc-364549A
sc-364549B
sc-364549C
sc-364549D
5 mg
25 mg
100 mg
500 mg
1 g
$90.00
$210.00
$375.00
$740.00
$1225.00
4
(1)

Targets HER2 and EGFR, Neratinib can disrupt cell signaling, potentially affecting protein functions.

Osimertinib

1421373-65-0sc-507355
5 mg
$86.00
(0)

A third-generation EGFR inhibitor, Osimertinib can modulate cell growth and survival pathways.

Vandetanib

443913-73-3sc-220364
sc-220364A
5 mg
50 mg
$167.00
$1353.00
(1)

Targets RET, VEGFR, and EGFR, Vandetanib can modulate critical signaling pathways, influencing protein activity.